DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 4,300,000 shares, a decrease of 14.9% from the September 30th total of 5,050,000 shares. Currently, 5.4% of the shares of the stock are sold short. Based on an average daily volume of 711,500 shares, the short-interest ratio is currently 6.0 days.

DaVita Stock Up 0.8 %

DVA traded up $1.27 during trading on Tuesday, hitting $158.32. The company had a trading volume of 1,266,738 shares, compared to its average volume of 805,333. The company has a market cap of $13.28 billion, a PE ratio of 16.86, a P/E/G ratio of 0.90 and a beta of 0.87. DaVita has a 1-year low of $75.47 and a 1-year high of $168.50. The business has a 50-day moving average of $158.40 and a 200-day moving average of $146.05. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.47 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to analysts' expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.08 EPS. As a group, analysts forecast that DaVita will post 9.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of analyst reports. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, August 8th. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. Bank of America lifted their target price on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. Finally, TD Cowen boosted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, DaVita has a consensus rating of "Hold" and a consensus price target of $159.00.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company's stock, valued at $138,284,666.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company's stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock worth $27,387,069 in the last 90 days. Insiders own 2.00% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in DaVita by 1.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company's stock valued at $18,612,000 after purchasing an additional 2,129 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of DaVita in the 1st quarter valued at $220,000. First Trust Direct Indexing L.P. lifted its position in DaVita by 3.9% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company's stock worth $358,000 after buying an additional 98 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in DaVita by 175.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company's stock worth $2,614,000 after buying an additional 12,064 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new position in DaVita during the 1st quarter worth about $2,899,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.